Jinling Pharmaceutical Company Limited (SHE:000919)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2019	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Jan 1, 2019	Dec 31, 2017	Dec 31, 2016
Medicine Production and Sales	1.49B	1.49B	1.55B	1.41B	1.48B
Medicine Production and Sales Growth	0.09%	-3.93%	10.24%	-4.64%	9.89%
Medical Services	1.65B	1.74B	1.57B	1.21B	1.29B
Medical Services Growth	-5.22%	10.83%	29.30%	-5.73%	14.68%
Others	53.65M	48.22M	69.79M	46.95M	42.38M
Others Growth	11.25%	-30.91%	48.64%	10.79%	20.16%
Total	3.20B	3.28B	3.19B	2.67B	2.81B
Total Growth	-2.56%	2.74%	19.58%	-4.91%	12.18%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2019	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Jan 1, 2019	Dec 31, 2017	Dec 31, 2016
North China	66.27M	62.35M	21.92M	14.77M	17.62M
North China Growth	6.29%	184.41%	48.46%	-16.22%	-
Northwest China	45.63M	41.36M	11.36M	8.43M	13.80M
Northwest China Growth	10.32%	264.25%	34.77%	-38.94%	-
Northeast China	13.51M	11.40M	16.23M	27.73M	33.06M
Northeast China Growth	18.53%	-29.78%	-41.48%	-16.11%	-
Xinjiang Region	2.96M	2.87M	5.54M	447.23K	1.05M
Xinjiang Region Growth	3.17%	-48.20%	1138.99%	-57.47%	-
Central and Southwest China	151.22M	146.00M	129.81M	105.77M	120.44M
Central and Southwest China Growth	3.57%	12.47%	22.73%	-12.19%	-
East China	2.91B	3.01B	3.01B	2.51B	2.62B
East China Growth	-3.28%	0.20%	19.74%	-4.31%	-
Overseas	5.44M	6.30M	3.91M	4.11M	-
Overseas Growth	-13.63%	61.17%	-4.99%	-	-
Total	3.20B	3.28B	3.19B	2.67B	2.81B
Total Growth	-2.56%	2.74%	19.58%	-4.91%	12.18%

Source: S&P Global Market Intelligence.